Pharma: Other news to note
Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, said the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted against the approval of the use of Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome in combination with standard antiplatelet therapy.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST